Milestones - i2medi

i2medi and Picis expand Partnership into Colombia

i2medi and Picis Expand Partnership into Colombia, Delivering Advanced Perioperative Clinical Solutions

21 new high technology rooms in México-City

I2medi México realizes 21 new operating rooms in México City

i2medi Mexico successfully certified for ISO 9001

2medi México successfully certified for ISO 9001!

KI for the new Alto Hospicio hospital in Chile

The i²medi Group implements successful project partnership in Chile.

Doctor Ulises Rojel Martinez, president of the Latin American Heart Rhythm Society

First Publication on initial Latin American Experience with CCM technology

The teams of i2medi -the official distributor of impulse dynamics (the CCM manufacturer) in Mexico
have been successfully trained and certified in Feb 2024.

Mexico-Cardiac Contractility Modulation (CCM) expanding rapidly

The teams of i2medi -the official distributor of impulse dynamics (the CCM manufacturer) in Mexico
have been successfully trained and certified in Feb 2024.

First implantation of SmartOptimzer in Mexico

Dr. Ulises Rojel, implants the Optimizer Smart at the Instituto del Corazón in Puebla, Mexico.

Cardisio

i2medi and the prestigious cardiology team at the IGESP hospital in Sao Paulo are currently conducting the first AI-based Cardisio study in Latin America.

Successful CAAC certification Colombia

Since April 2023, i²medi S.A.S., based in Colombia, has been acting as an official importer of controlled and non-controlled medical devices in the Colombian market.

EMB use is recommended in the new Brazilian myocarditis guidelines.

Sustainable and strategic product positioning in the key markets of Latin America (BRA, COL and MEX) ...

COFEPRIS MEX Regulatory approval

On March 15, 2023, the Mexican authority “COFEPRIS”, responsible for the product approval of new medical technology products,
approved the Smart Optimizer from Impulse Dynamics - Class 3.

Inclusion of CCM in the Brazilian guidelines for implantable electronic devices - 2023

The Brazilian Society of Cardiology recommends Cardiac Contractility Modulation (CCM) therapy as an option for the treatment of heart failure patients without indication for CRT, with narrow QRS (< 130 ms) and LVEF between 25% and 45%.

Implementation of scientific studies: i²medi / Impulse Dynamics sponderdern InCor study FIX Chagas HF

InCor (Instituto do Coração - Hospital of the University of São Paulo - HCFMUSP) initiates the world's first randomized clinical trial of Cardiac Contractility Modulation (CCM) in patients with Chagas disease.

Digital continuing education for the public health system

In collaboration with the Colombian Osteoporosis Association ACOMM, we have ...

User training R.E.M.S. technology (Echolight)

Successful user training course for 59 participants on R.E.M.S. technology with ...

Development of return of investment calculation tools

For the company Caresyntax, OP video and data integration systems, we have developed a ...

Coordinated studies First Latin American clinical trial of R.E.M.S. technology

First Software-as-a-Service (SAAS) sales contract for new OR performance management software in LATAM

i2medi has managed to successfully conclude the first contract with the most modern hospital for the treatment of cancer in LATAM (CTIC).

First implantation and commercial success with new technology in heart failure

i2medi has launched the distribution of cardiac contractility modulation in Brazil ...

Establishment and commercial usage of reference sites - Los Cobos - Bogotá

i2medi, together with its local strategic partners, organized a major launch event at the ...

Product approval class IIb in Mexico < than 6 months

Our local team in Mexico achieved product registration approval on the fly.

High 6-digit project profit in the area of hospital infrastructure

Sustainable and strategic product positioning in the key markets of Latin America (BRA, COL and MEX)

Support

Get in touch

About us